Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$84.23 - $154.61
Previous CloseN/A
Volume209.65K
Average Volume (3M)783.69K
Market Cap
$14.54B
Enterprise Value$12.21B
Total Cash (Recent Filing)$975.60M
Total Debt (Recent Filing)$439.10M
Price to Earnings (P/E)43.2
Beta0.62
Next Earnings
Nov 04, 2025EPS Estimate
1.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.06
Shares Outstanding99,181,510
10 Day Avg. Volume772,466
30 Day Avg. Volume783,692
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue4.86
Enterprise Value/Gross Profit4.94
Enterprise Value/Ebitda21.91
Forecast
1Y Price Target
$168.73Price Target Upside15.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering25
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase II Savitri trial of osavampator showed positive results in patients with major depressive disorder who had an inadequate response to previous therapies.
Drug DevelopmentThe lower 1 mg osa’ dose demonstrated a statistically significant improvement in MADRS at Day 28 and Day 56.
Product LaunchThe Crenessity launch has been solid beating both the company's and investor expectations, and management is pleased with the performance so far.
Bears Say
Market CompetitionIngrezza remains a solid performer and continues to be education/promotion sensitive even as there is some uncertainty as competitor Teva's Austedo/Austedo XR becomes subject to the impact of the Inflation Reduction Act (IRA) in 2027.
Operational ChallengesOffice visits are a rate limiter to getting patients on Crenessity therapy, especially during slower summer periods.
Neurocrine News
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $84.23 and its highest was $154.61 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $14.54B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Nov 04, 2025 which is in 40 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Jul 30, 2025. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.965 by $0.095.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 1.56.
How many shares outstanding does Neurocrine have?
Neurocrine has 99,181,510 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.06 in its last earnings report, beating expectations of $0.965. Following the earnings report the stock price went down -6.237%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
Neurocrine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$168.73 (15.04% Upside)
$168.73 (15.04% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 663.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.33%
12-Months-Change
Fundamentals
Return on Equity
13.39%
Trailing 12-Months
Asset Growth
17.69%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
NBIX Company Deck
NBIX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and successful product launches, particularly with CRENESSITY and INGREZZA, alongside robust pipeline development. However, there are notable challenges such as the failure of the valbenazine study to meet its primary endpoint and pricing pressures on INGREZZA. Despite these challenges, the overall sentiment reflects confidence in continued growth and strategic investments.View all NBIX earnings summariesNBIX Stock 12 Month Forecast
Average Price Target
$168.73
▲(15.04% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
Amphastar Pharmaceuticals
―
Ownership Overview
1.10% Insiders
30.89% Mutual Funds
25.38% Other Institutional Investors
16.00% Public Companies and
Individual Investors